A panel of systemic inflammatory response biomarkers for outcome prediction in patients treated with radical cystectomy for urothelial carcinoma

Schuettfort, Victor M.; D’Andrea, David; Quhal, Fahad; Mostafaei, Hadi; Laukhtina, Ekaterina; Mori, Keiichiro; König, Frederik; Rink, Michael; Abufaraj, Mohammad; Karakiewicz, Pierre I.; Luzzago, Stefano; Rouprêt, Morgan; Enikeev, Dmitry; Zimmermann, Kristin; Deuker, Marina; Moschini, Marco; Motlagh, Reza Sari; Grossmann, Nico C.; Katayama, Satoshi; Pradère, Benjamin; Shariat, Shahrokh F.

doi:10.1111/bju.15379

Cited by 20 publications

(39 citation statements)

References 44 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…(6) the design type of the study is a retrospective study and prospective study. (7) the research, which is rated as high quality by the study quality evaluation system. Also, repetitive studies, letters, case reports, reviews, studies unrelated to the subject matter, experimental results from computer models, animal experiments, and theoretical experiments, and studies that could not extract available data were excluded.…”

Section: Literature Search and Eligibility Criteriamentioning

confidence: 99%

“…Any pathological type of bladder cancer has a recurrence, fatal complications, and poor prognosis after treatment. At present, a lot of studies have proved that some genes, the ratio of fibrinogen to serum albumin, the percentage of neutrophils to lymphocytes, and the modified Glasgow Prognostic Score (GPS) can be used to assess the prognosis of BC (5)(6)(7). UTUC includes ureteral cancer and renal pelvic cancer, with a low incidence, accounting for less than 10% of urothelial cancers.…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Controlling Nutritional Status Score Before Receiving Treatment as a Prognostic Indicator for Patients With Urothelial Cancer: An Exploration Evaluation Methods

Peng

Meng

et al. 2021

Front. Oncol.

View full text Add to dashboard Cite

IntroductionThis meta-analysis aims to assess whether the Controlling nutritional status (CONUT) score before treatment can be an independent predictor of the prognosis of patients with urothelial cancer (UC).MethodsThe system searches Web of Science, PubMed, MEDLINE, China National Knowledge Infrastructure (CNKI), and Cochrane Library, and the search time is up to April 2021. Use STATA 16.0 and Engauge Digitizer 4.1 software for data processing and statistical analysis.ResultsA total of 8 studies were included in this meta-analysis. The meta-analysis results show that compared with the low CONUT group, the high CONUT group has worse over survival (OS) [HR=1.58, 95%CI (1.34, 1.86), P=0.001], cancer-specific survival (CSS) [HR=2.03, 95%CI (1.25-3.29), P=0.04] and recurrence-free survival (RFS) [HR=1.97, 95%CI (1.15, 3.40), P=0.014]; for progression-free survival (PFS), or disease-free survival (DFS), the difference between the two groups was not statistically significant [HR=2.30, 95%CI (0.72, 7.32), P=0.158]. According to different carcinoma types, cut-off value, and region, subgroup analysis of OS was performed, and similar results were obtained.ConclusionsBased on current evidence, this meta-analysis proves that the CONUT score of UC patients before treatment is an independent prognostic predictor. It performs well on OS, CSS, and RFS, but the conclusions on DFS/PFS need to be treated with caution.Systematic Review Registrationhttps://www.crd.york.ac.uk/prospero/display_record.php?ID=CRD42021251890, identifier CRD42021251890.

show abstract

Section: Literature Search and Eligibility Criteriamentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

Controlling Nutritional Status Score Before Receiving Treatment as a Prognostic Indicator for Patients With Urothelial Cancer: An Exploration Evaluation Methods

Peng

Meng

et al. 2021

Front. Oncol.

View full text Add to dashboard Cite

show abstract

“…6,7 Previously investigated prognostic and predictive blood-based biomarkers in patients treated with RC for UC either do not offer a clinically meaningfully discriminative ability and/or lack external validation. [8][9][10][11][12][13][14][15][16] IGF-I is produced by liver cells, 17 tumor cells, and cancerassociated macrophages. 17 The IGF-I signaling pathway, including IGF-I itself, the circulating levels of IGFBPs, and its tissue receptors (IGF-IR) have been found to promote tumor cell proliferation, metastasis, and drug resistance.…”

Section: Introductionmentioning

confidence: 99%

Prognostic impact of insulin‐like growth factor‐I and its binding proteins, insulin‐like growth factor‐I binding protein‐2 and ‐3, on adverse histopathological features and survival outcomes after radical cystectomy

et al. 2022

Self Cite

View full text Add to dashboard Cite

Abbreviations & Acronyms AUC = area under the curve CI = confidence interval CIS = carcinoma in situ CSS = cancer-specific survival DCA = decision curve analysis HR = hazard ratio IGFBP = insulin-like growth factor-I binding protein IGF-I = insulin-like growth factor-I IGF-IR = insulin-like growth factor-I receptor IQR = interquartile range LNM = lymph node metastasis NOCD = non-organ confined disease OR = odds ratio OS = overall survival RC = radical cystectomy RFS = recurrence-free survival ROC = receiver operating characteristic SE = standard error UC = urothelial carcinoma

show abstract

“…In addition, the value of inflammatory indexes including lymphocyte-to-monocyte ratio, platelet-tolymphocyte ratio, and neutrophil-to-lymphocyte ratio were estimated in new bladder cancer cases. Moreover, studies showed that these markers were the independent predictors for OS in bladder cancer (10)(11)(12). In the Glasgow prognosis model, C-reactive protein and albumin were independent prognostic factors in tumors (13).…”

Section: Introductionmentioning

confidence: 99%

Development and Validation of Prognostic Model in Transitional Bladder Cancer Based on Inflammatory Response-Associated Genes

Xie

Cai²,

Sun³

et al. 2021

Front. Oncol.

View full text Add to dashboard Cite

BackgroundBladder cancer is a common malignant type in the world, and over 90% are transitional cell carcinoma. While the impact of inflammatory response on cancer progression has been reported, the role of inflammatory response-associated genes (IRAGs) in transitional bladder cancer still needs to be understood.MethodsIn this study, IRAGs were download from Molecular Signature Database (MSigDB). The transcriptional expression and matched clinicopathological data were separately obtained from public databases. The TCGA-BLCA cohort was used to identify the differentially expressed IRAGs, and prognostic IRAGs were filtrated by univariate survival analysis. The intersection between them was displayed by Venn diagram. Based on least absolute shrinkage and selection operator (LASSO) regression analysis method, the TCGA-BLCA cohort was used to construct a risk signature. Survival analysis was conducted to calculate the overall survival (OS) in TCGA and GSE13507 cohort between two groups. We then conducted univariate and multivariate survival analyses to identify independently significant indicators for prognosis. Relationships between the risk scores and age, grade, stage, immune cell infiltration, immune function, and drug sensitivity were demonstrated by correlation analysis. The expression level of prognostic genes in vivo and in vitro were determined by qRT-PCR assay.ResultsComparing with normal tissues, there were 49 differentially expressed IRAGs in cancer tissues, and 12 of them were markedly related to the prognosis in TCGA cohort for transitional bladder cancer patients. Based on LASSO regression analysis, a risk model consists of 10 IRAGs was established. Comparing with high-risk groups, survival analysis showed that patients in low-risk groups were more likely to have a better survival time in TCGA and GSE13507 cohorts. Besides, the accuracy of the model in predicting prognosis is acceptable, which is demonstrated by receiver operating characteristic curve (ROC) analysis. Age, stage, and risk scores variables were identified as the independently significant indicators for survival in transitional bladder cancer. Correlation analysis represented that the risk score was identified to be significantly related to the above variables except gender variable. Moreover, the expression level of prognostic genes in vivo and in vitro was markedly upregulated for transitional bladder cancer.ConclusionsA novel model based on the 10 IRAGs that can be used to predict survival time for transitional bladder cancer. In addition, this study may provide treatment strategies according to the drug sensitivity in the future.

show abstract

A panel of systemic inflammatory response biomarkers for outcome prediction in patients treated with radical cystectomy for urothelial carcinoma

Abstract: To determine the predictive and prognostic value of a panel of systemic inflammatory response (SIR) biomarkers relative to established clinicopathological variables in order to improve patient selection and facilitate more efficient delivery of perioperative systemic therapy.

Cited by 20 publications

References 44 publications

Controlling Nutritional Status Score Before Receiving Treatment as a Prognostic Indicator for Patients With Urothelial Cancer: An Exploration Evaluation Methods

Controlling Nutritional Status Score Before Receiving Treatment as a Prognostic Indicator for Patients With Urothelial Cancer: An Exploration Evaluation Methods

Prognostic impact of insulin‐like growth factor‐I and its binding proteins, insulin‐like growth factor‐I binding protein‐2 and ‐3, on adverse histopathological features and survival outcomes after radical cystectomy

Development and Validation of Prognostic Model in Transitional Bladder Cancer Based on Inflammatory Response-Associated Genes

Contact Info

Product

Resources

About